FindTrial
Sign In

Comparison of two chemotherapeutic drug combinations for lung cancer.

Treatment response and toxicity profile of Pemetrexed/carboplatin vs Paclitaxel/carboplatin combination chemotherapy schedule in advanced non-small cell lung cancer( adenocarcinoma) patients-A prospective observational study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019130
Enrollment
154
Registered
2019-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Advanced non-small cell lung cancer( adenocarcinoma) patients Health Condition 2: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung Health Condition 3: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung Health Condition 4: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung

Interventions

Intervention1: Pemetrexed/carboplatin: Intravenous Pemetrexed 500mg/m2 three weekly for four cycles and intravenous carboplatin AUC 5 three weekly four cycles followed by maintenance pemetrexed 500mg/

Sponsors

Government medical college hospital Trivandrum
Lead Sponsor
Dr K L Jayakumar
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed cases of non small cell lung cancer â??adenocarcinoma 2. Stage 3B and Stage 4. 3. EGFR nonmutated or not done. 4. Eastern cooperative oncology group (ECOG) performance status of 1 or 2. 5. Previously untreated cases. 6. Normal bone marrow function(Hb >10, TC >4000, PLC >1Lakh) 7. Normal renal function (serum creatinine 8. Normal liver function.

Exclusion criteria

Exclusion criteria: 1. Patients not willing to give a written consent. 2. History of previous malignancies treated or untreated. 3. Clinically significant cardiovascular disease, haemorrhagic diasthesis ,peripheral neuropathy ,coagulopathy. 4. EGFR mutated.

Design outcomes

Primary

MeasureTime frame
Tumor response to Pemetrexed / Carboplatin versus Paclitaxel / Carboplatin in advanced Non Small Cell Lung Cancer(adenocarcinoma)Timepoint: 12 weeks from start of chemotherapy—

Secondary

MeasureTime frame
The progression free survival. Timepoint: Till one and half year from start of study;The toxicity profile Timepoint: After each chemotherapy cycle—

Countries

India

Contacts

Public ContactAarani Devi

Department of Radiotherapy & Oncology

drkljayakumar@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026